S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Israel hails 'success' in blocking Iran's unprecedented attack. Biden now seeks diplomatic response
Germany's Scholz arrives in China on a visit marked by trade tensions and Ukraine conflict
Diplomat tapped as Latvia's new foreign minister as incumbent quits following flights scandal
India's Modi vows to boost social spending, make country into a manufacturing hub ahead of election
It's almost April 15. Here's how to reduce stress and get your taxes done
Can homeless people be fined for sleeping outside? A rural Oregon city asks the US Supreme Court
Olympic track uniforms spark online debate about who designed them and why they're so skimpy
NASDAQ:ACET

Adicet Bio (ACET) Stock Price, News & Analysis

$2.16
-0.08 (-3.57%)
(As of 04/12/2024 ET)
Today's Range
$2.14
$2.22
50-Day Range
$1.95
$3.38
52-Week Range
$1.10
$7.50
Volume
416,385 shs
Average Volume
1.08 million shs
Market Capitalization
$177.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.83

Adicet Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
494.1% Upside
$12.83 Price Target
Short Interest
Bearish
9.36% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Adicet Bio in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$7.50 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.72) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.57 out of 5 stars

Medical Sector

533rd out of 925 stocks

Pharmaceutical Preparations Industry

244th out of 427 stocks

ACET stock logo

About Adicet Bio Stock (NASDAQ:ACET)

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.

ACET Stock Price History

ACET Stock News Headlines

Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update
ACET Adicet Bio, Inc.
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification
JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)
ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023
Adicet Bio: Q4 Earnings Insights
Adicet Bio, Inc Q4 loss drops in line with estimates
7 Top-Tier Penny Stocks for a Smart Bet
ACET Apr 2024 7.500 call
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/14/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
143
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.83
High Stock Price Target
$27.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+494.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-142,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$24.99 million
Book Value
$2.43 per share

Miscellaneous

Free Float
57,919,000
Market Cap
$177.44 million
Optionable
Optionable
Beta
1.88
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Chen  Schor BAMr. Chen Schor BA (Age 52)
    CPA, M.B.A., CEO, President & Director
    Comp: $899.58k
  • Dr. Aya Jakobovits Ph.D. (Age 68)
    Founder & Independent Director
    Comp: $40k
  • Dr. Blake Aftab Ph.D. (Age 43)
    Senior VP & Chief Scientific Officer
    Comp: $675.04k
  • Dr. Francesco Galimi M.D. (Age 56)
    Ph.D., Chief Medical Officer & Senior VP
    Comp: $680.37k
  • Mr. Brian Nicholas Harvey (Age 63)
    Chief Financial Officer
    Comp: $596.79k
  • Dr. Donald Healey Ph.D. (Age 62)
    Chief Technology Officer
  • Ms. Amy Locke
    Chief Human Resource Officer
  • Dr. Nancy L. Boman M.D.
    Ph.D., Senior VP & Chief Regulatory Officer

ACET Stock Analysis - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings
or view top-rated stocks.

What is Adicet Bio's stock price target for 2024?

8 equities research analysts have issued 12-month price targets for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they predict the company's share price to reach $12.83 in the next year. This suggests a possible upside of 494.1% from the stock's current price.
View analysts price targets for ACET
or view top-rated stocks among Wall Street analysts.

How have ACET shares performed in 2024?

Adicet Bio's stock was trading at $1.89 at the beginning of the year. Since then, ACET shares have increased by 14.3% and is now trading at $2.16.
View the best growth stocks for 2024 here
.

Are investors shorting Adicet Bio?

Adicet Bio saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 7,690,000 shares, an increase of 32.4% from the March 15th total of 5,810,000 shares. Based on an average daily trading volume, of 1,690,000 shares, the days-to-cover ratio is currently 4.6 days.
View Adicet Bio's Short Interest
.

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ACET earnings forecast
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Tuesday, March, 19th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.03.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACET) was last updated on 4/14/2024 by MarketBeat.com Staff

From Our Partners